INSL5 is a novel marker for human enteroendocrine cells of the large intestine and neuroendocrine tumours

Thanasupawat,Thatchawan; Hammje,Katrin; Adham,Ibrahim; Ghia,Jean-Eric; Del Bigio,Marc  R.; Krcek,Jerry; Hoang-Vu,Cuong; Klonisch,Thomas; Hombach-Klonisch,Sabine

doi:10.3892/or.2012.2119

INSL5 is a novel marker for human enteroendocrine cells of the large intestine and neuroendocrine tumours

Authors:
- Thatchawan Thanasupawat
- Katrin Hammje
- Ibrahim Adham
- Jean-Eric Ghia
- Marc R. Del Bigio
- Jerry Krcek
- Cuong Hoang-Vu
- Thomas Klonisch
- Sabine Hombach-Klonisch
View Affiliations

Affiliations: Department of Human Anatomy and Cell Science, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada, Clinics of General, Visceral and Vascular Surgery, Martin Luther University (MLU), Halle-Wittenberg, Germany, Institute of Human Genetics, University of Göttingen, Göttingen, Germany, Department of Internal Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
Published online on: October 31, 2012 https://doi.org/10.3892/or.2012.2119
Pages: 149-154

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We report for the first time the distribution of human INSL5 and its cognate leucine rich G-protein coupled receptor RXFP4 in the large intestine and in neuroendocrine/carcinoid tissues. Immunoreactive INSL5 was uniquely expressed by enteroendocrine cells (EECs) located within the colonic mucosa, whereas colonocytes were immunopositive for RXFP4. INSL5+ and RXFP4+ cells were also detected in human neuroendocrine/carcinoid tissues. We employed a recently described Insl5 knockout mouse model and 2 mouse models of induced colitis to address the relevance of Insl5 in EEC development and in acute inflammation of the colon. We identified INSL5 as a specific marker for synaptophysin+ EECs in the mucosa of the normal human and mouse colon. Insl5 was not essential for the development of mouse synaptophysin+ EECs. The mouse models of chemically induced colitis (dextran sulfate sodium and dinitrobenzene-sulfonic acid) failed to show changes in the numbers of Insl5+ EECs at inflammatory sites during the acute phase of colitis. In conclusion, we showed that INSL5 is a novel marker of colorectal EECs and provide first evidence for the presence of a potentially autocrine/paracrine INSL5-RXFP4 signaling system in the normal human and mouse colon and in rare human neuroendocrine tumours.

View Figures

View References

1	Wilkinson TN, Speed TP, Tregear GW and Bathgate RA: Evolution of the relaxin-like peptide family. BMC Evol Biol. 5:142005. View Article : Google Scholar : PubMed/NCBI
2	Conklin D, Lofton-Day CE, Haldeman BA, et al: Identification of INSL5, a new member of the insulin superfamily. Genomics. 60:50–56. 1999. View Article : Google Scholar : PubMed/NCBI
3	Liu C, Kuei C, Sutton S, et al: INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J Biol Chem. 280:292–300. 2005. View Article : Google Scholar : PubMed/NCBI
4	Liu C and Lovenberg TW: Relaxin-3, INSL5, and their receptors. Results Probl Cell Differ. 46:213–237. 2008. View Article : Google Scholar
5	Liu C, Chen J, Kuei C, et al: Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Mol Pharmacol. 67:231–240. 2005. View Article : Google Scholar : PubMed/NCBI
6	Chen J, Kuei C, Sutton SW, et al: Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species. J Pharmacol Exp Ther. 312:83–95. 2005. View Article : Google Scholar : PubMed/NCBI
7	Liu C, Eriste E, Sutton S, et al: Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem. 278:50754–50764. 2003. View Article : Google Scholar
8	Field BC, Chaudhri OB and Bloom SR: Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol. 6:444–453. 2010. View Article : Google Scholar : PubMed/NCBI
9	Khan WI and Ghia JE: Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 161:19–27. 2010.PubMed/NCBI
10	Moran GW, Leslie FC, Levison SE, Worthington J and McLaughlin JT: Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol. 1:51–60. 2008. View Article : Google Scholar : PubMed/NCBI
11	Rindi G, Leiter AB, Kopin AS, Bordi C and Solcia E: The ‘normal’ endocrine cell of the gut: changing concepts and new evidences. Ann NY Acad Sci. 1014:1–12. 2004.
12	Andrew A, Kramer B and Rawdon BB: The origin of gut and pancreatic neuroendocrine (APUD) cells - the last word? J Pathol. 186:117–118. 1998. View Article : Google Scholar : PubMed/NCBI
13	Gordon JI: Understanding gastrointestinal epithelial cell biology: lessons from mice with help from worms and flies. Gastroenterology. 105:315–324. 1993.PubMed/NCBI
14	Schonhoff SE, Giel-Moloney M and Leiter AB: Minireview: Development and differentiation of gut endocrine cells. Endocrinology. 145:2639–2644. 2004. View Article : Google Scholar : PubMed/NCBI
15	May CL and Kaestner KH: Gut endocrine cell development. Mol Cell Endocrinol. 323:70–75. 2010. View Article : Google Scholar
16	Wiedenmann B, Franke WW, Kuhn C, Moll R and Gould VE: Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA. 83:3500–3504. 1986. View Article : Google Scholar : PubMed/NCBI
17	Gunawardene AR, Corfe BM and Staton CA: Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol. 92:219–231. 2011. View Article : Google Scholar : PubMed/NCBI
18	West NE, Wise PE, Herline AJ, Muldoon RL, Chopp WV and Schwartz DA: Carcinoid tumors are 15 times more common in patients with Crohn’s disease. Inflamm Bowel Dis. 13:1129–1134. 2007.PubMed/NCBI
19	Kang H, O’Connell JB, Leonardi MJ, Maggard MA, McGory ML and Ko CY: Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 22:183–189. 2007. View Article : Google Scholar : PubMed/NCBI
20	Soga J: Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 22:517–530. 2003.PubMed/NCBI
21	Modlin IM and Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer. 79:813–829. 1997. View Article : Google Scholar : PubMed/NCBI
22	Modlin IM, Lye KD and Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 97:934–959. 2003. View Article : Google Scholar : PubMed/NCBI
23	Soga J: Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer. 103:1587–1595. 2005. View Article : Google Scholar : PubMed/NCBI
24	Grabowski P, Schonfelder J, Ahnert-Hilger G, et al: Heterogeneous expression of neuroendocrine marker proteins in human undifferentiated carcinoma of the colon and rectum. Ann NY Acad Sci. 1014:270–274. 2004. View Article : Google Scholar : PubMed/NCBI
25	Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 98:694–702. 1990.PubMed/NCBI
26	Sturiale S, Barbara G, Qiu B, et al: Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci USA. 96:11653–11658. 1999. View Article : Google Scholar
27	Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI and Collins SM: Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology. 136:2280–2288. 2009. View Article : Google Scholar : PubMed/NCBI
28	Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238–249. 1993.PubMed/NCBI
29	Burnick-Turek O, Mohamed BA, Shirneshan K, et al: INSL5-deficient mice display an alteration in glucose homeostasis and impaired fertility. Endocrinology. 153:4655–4665. 2012. View Article : Google Scholar : PubMed/NCBI
30	Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G and Blanchard JF: Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 95:677–683. 2000. View Article : Google Scholar : PubMed/NCBI
31	El-Salhy M, Danielsson A, Stenling R and Grimelius L: Colonic endocrine cells in inflammatory bowel disease. J Intern Med. 242:413–419. 1997. View Article : Google Scholar : PubMed/NCBI
32	Wang H, Steeds J, Motomura Y, et al: CD4⁺ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. Gut. 56:949–957. 2007.
33	Ahonen A, Kyosola K and Penttila O: Enterochromaffin cells in macrophages in ulcerative colitis and irritable colon. Ann Clin Res. 8:1–7. 1976.PubMed/NCBI
34	Klonisch T, Bialek J, Radestock Y, Hoang-Vu C and Hombach-Klonisch S: Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. Adv Exp Med Biol. 612:104–118. 2007. View Article : Google Scholar
35	Jaspers S, Lok S, Lofton-Day CE, et al: The Genomics of Insulin 5. Kluwer Academic Publishers; Dordrecht: 2001
36	Jahn R, Schiebler W, Ouimet C and Greengard P: A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA. 82:4137–4141. 1985. View Article : Google Scholar : PubMed/NCBI
37	Gould VE, Lee I, Wiedenmann B, Moll R, Chejfec G and Franke WW: Synaptophysin: a novel marker for neurons, certain neuroendocrine cells, and their neoplasms. Hum Pathol. 17:979–983. 1986. View Article : Google Scholar : PubMed/NCBI
38	Buffa R, Rindi G, Sessa F, et al: Synaptophysin immunoreactivity and small clear vesicles in neuroendocrine cells and related tumours. Mol Cell Probes. 1:367–381. 1987. View Article : Google Scholar : PubMed/NCBI
39	Bjerknes M and Cheng H: Neurogenin 3 and the enteroendocrine cell lineage in the adult mouse small intestinal epithelium. Dev Biol. 300:722–735. 2006. View Article : Google Scholar : PubMed/NCBI
40	Cortina G, Smart CN, Farmer DG, et al: Enteroendocrine cell dysgenesis and malabsorption, a histopathologic and immunohistochemical characterization. Hum Pathol. 38:570–580. 2007. View Article : Google Scholar : PubMed/NCBI
41	Skipper M and Lewis J: Getting to the guts of enteroendocrine differentiation. Nat Genet. 24:3–4. 2000. View Article : Google Scholar : PubMed/NCBI
42	Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH and Polak JM: Increased populations of endocrine cells in Crohn’s ileitis. Virchows Arch A Pathol Anat Histopathol. 410:391–396. 1987.PubMed/NCBI
43	Linden DR, Chen JX, Gershon MD, Sharkey KA and Mawe GM: Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 285:G207–G216. 2003. View Article : Google Scholar : PubMed/NCBI
44	Oshima S, Fujimura M and Fukimiya M: Changes in number of serotonin-containing cells and serotonin levels in the intestinal mucosa of rats with colitis induced by dextran sodium sulfate. Histochem Cell Biol. 112:257–263. 1999. View Article : Google Scholar : PubMed/NCBI
45	O’Hara JR, Ho W, Linden DR, Mawe GM and Sharkey KA: Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol. 287:G998–G1007. 2004.PubMed/NCBI
46	Ghia JE, Li N, Wang H, et al: Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology. 137:1649–1660. 2009. View Article : Google Scholar : PubMed/NCBI
47	Feng S, Agoulnik IU, Truong A, et al: Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 17:1021–1033. 2010. View Article : Google Scholar : PubMed/NCBI
48	Vinall RL, Mahaffey CM, Davis RR, et al: Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2:224–238. 2011.
49	Hombach-Klonisch S, Bialek J, Radestock Y, et al: INSL3 has tumor-promoting activity in thyroid cancer. Int J Cancer. 127:521–531. 2010. View Article : Google Scholar : PubMed/NCBI
50	Akhter Hossain M, Bathgate RA, Kong CK, et al: Synthesis, conformation, and activity of human insulin-like peptide 5 (INSL5). Chembiochem. 9:1816–1822. 2008.PubMed/NCBI
51	Belgi A, Hossain MA, Shabanpoor F, et al: Structure and function relationship of murine insulin-like peptide 5 (INSL5): free C-terminus is essential for RXFP4 receptor binding and activation. Biochemistry. 50:8352–8361. 2011. View Article : Google Scholar : PubMed/NCBI